Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss
Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO:
Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company
transforming the lives of patients through a novel class of in vivo
reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President
and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative
medicine, today announced that they have executed a collaborative
research agreement on in vivo regenerative medicine approaches to
address sensorineural hearing loss.
More info >> |
